Calico and AbbVie Take UCSF Technology Into Clinical Trials

Calico Life Sciences and AbbVie announced clinical-stage programs in two areas – immuno-oncology and neurodegeneration, currently in Phase I studies. The lead Calico neurodegeneration molecule is based on novel technology licensed from the lab of Peter Walter, Professor of Biochemistry and Biophysics at the University of California, San Francisco.